Design of the NOVA Trial for Ovarian Cancer

Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.

Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.

The NOVA trial aimed to determine whether the PARP inhibitor niraparib improves progression-free survival (PFS), with other endpoints being overall survival, time to first subsequent therapy, chemotherapy free interval, and other quality of life measures.